Alligator Bioscience
Research Alligator Bioscience (ATORX.ST) on Bullrun: market cap SEK 64.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATORX.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 64.23M
- Financial periodQ1 2026
- RevenueSEK 0
- Net incomeSEK 1.44M
- Free cash flow-SEK 38.65M
Valuation Snapshot
latest market cap is SEK 64.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -1.4 | SEK 62.20M | SEK 43.15M | SEK 6.86M |
| FY2024 | SEK 57.77M | -SEK 233.89M | -SEK 212.43M | n/a | -0.32 | SEK 64.31M | SEK 180.81M | -SEK 130.59M |
| FY2023 | SEK 58.11M | -SEK 248.59M | -SEK 191.74M | n/a | -0.55 | SEK 66.12M | n/a | SEK 11.86M |
| FY2022 | SEK 35.70M | -SEK 193.40M | -SEK 173.05M | n/a | -0.88 | SEK 97.31M | n/a | SEK 89.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 64.23M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Alligator Bioscience
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alligator Bioscience's market cap?
Alligator Bioscience's market capitalization is SEK 64.23M.
What does Alligator Bioscience do?
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.